AlgoNomics NV has announced it has entered into a research collaboration with Genmab A/S. In the collaboration, AlgoNomics will employ its antibody structure database and Tripole® technology to assist Genmab in research related to the structural analysis of Genmab’s proprietary antibody scaffolds, including the UniBody® technology.
The research collaboration focuses on the structural properties of fully human antibody and UniBody® molecules. Detailed analysis of such structural properties can provide insights into their specific function or therapeutic activity.
By combining experimental observations with such analyses from AlgoNomics Tripole® technology and antibody structure database, it may be possible to further improve on the properties of these antibodies.
Ignace Lasters, CSO of AlgoNomics, comments: “We are very pleased to be working again with Genmab. Combining our structural perspective with the outstanding biological and clinical insights of their discovery and development teams may accelerate the development of Genmab’s UniBody® technology.”
Under the agreement, AlgoNomics is eligible for research funding and subsequent potential milestone payments from Genmab. Other financial details and the therapeutic focus of the collaboration were not disclosed.